Literature DB >> 15538745

5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.

Yan-Ru Lou1, Nadja Nazarova, Riikka Talonpoika, Pentti Tuohimaa.   

Abstract

BACKGROUND: A cross-talk between 1alpha,25-dihydroxyvitamin D(3) [1alpha,25-(OH)(2)D(3)] and 5alpha-dihydrotestosterone (DHT) in the growth inhibition has been demonstrated, but the mechanism is unknown.
METHODS: The expression of 25-hydroxyvitamin D(3) 24-hydroxylase (24-hydroxylase) was measured using a real-time quantitative RT-PCR assay and the catabolism of 1alpha,25-(OH)(2)D(3) was measured using a radioreceptor assay.
RESULTS: Real-time RT-PCR showed that DHT at 1-100 nM significantly inhibited 1alpha,25-(OH)(2)D(3)-induced expression of 24-hydroxylase in LNCaP cells. Furthermore, the catabolism of 1alpha,25-(OH)(2)D(3) was decreased by 10 nM DHT. An androgen receptor (AR) antagonist, Casodex antagonized the DHT effect, whereas an AR agonist (due to the mutant AR in LNCaP cells) hydroxyflutamide did not.
CONCLUSIONS: We demonstrated, for the first time, that DHT reduces the ability of 1alpha,25-(OH)(2)D(3) to induce 24-hydroxylase expression. Our results not only support the earlier finding of a cross-talk between androgen and vitamin D in human prostate cancer cells but also provide a possible mechanism how androgen and vitamin D signaling pathways may interact. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15538745     DOI: 10.1002/pros.20189

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.

Authors:  Waise Quarni; Panida Lungchukiet; Anfernee Tse; Pei Wang; Yuefeng Sun; Ravi Kasiappan; Jheng-Yu Wu; Xiaohong Zhang; Wenlong Bai
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-01       Impact factor: 4.292

Review 2.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

3.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Authors:  Eleni Efstathiou; Mark Titus; Dimitra Tsavachidou; Vassiliki Tzelepi; Sijin Wen; Anh Hoang; Arturo Molina; Nicole Chieffo; Lisa A Smith; Maria Karlou; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

4.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

5.  GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.

Authors:  Omar Flores; Kerry L Burnstein
Journal:  Endocrinology       Date:  2010-08-25       Impact factor: 4.736

6.  The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

Authors:  Jung-Sun Kim; Justin M Roberts; William E Bingman; Longjiang Shao; Jianghua Wang; Michael M Ittmann; Nancy L Weigel
Journal:  Endocrinology       Date:  2014-06-13       Impact factor: 4.736

7.  Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2.

Authors:  Min Cui; Yan Zhao; Kenneth W Hance; Andrew Shao; Richard J Wood; James C Fleet
Journal:  J Cell Physiol       Date:  2009-04       Impact factor: 6.384

8.  The effect of differentiation on 1,25 dihydroxyvitamin D-mediated gene expression in the enterocyte-like cell line, Caco-2.

Authors:  Min Cui; Anna Klopot; Yan Jiang; James C Fleet
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

9.  Vitamin d, sunlight and prostate cancer risk.

Authors:  Krishna Vanaja Donkena; Charles Y F Young
Journal:  Adv Prev Med       Date:  2011-06-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.